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Background: Amyotrophic lateral sclerosis (ALS) is defined as
a disease of the motor neurones, although several studies
indicate involvement of the sensory nervous system.
Aim: To evaluate the sensory nerve conduction studies (NCS) in
88 patients with ALS as part of a European multicentre study.
Methods: Seven European clinical neurophysiologists exam-
ined consecutive series of ALS patients. The examinations were
peer reviewed, and the diagnosis of ALS was confirmed
clinically.
Results: 20 (22.7%) patients with ALS had sensory NCS
abnormalities in at least one nerve. Of those, 11 (12.5% of
all patients) obtained an additional peer review diagnosis of
electrophysiological polyneuropathy. There was no difference
between the subgroups of patients with normal versus
abnormal sensory NCS findings with respect to age, duration
and region of onset.
Conclusion: The findings support previous reports of sensory
involvement in ALS, and raise the question of whether patients
with ALS with sensory nerve abnormalities represent a variant
of ALS. ALS associated with generalised sensory system
abnormalities may be consistent with degeneration of motor
neurones and dorsal root ganglion cells.
S
poradic amyotrophic lateral sclerosis (ALS) is defined as a
progressive degeneration of upper motor neurones
(UMNs) and lower motor neurones (LMNs). Normal
electrophysiological studies on sensory nerves are generally
required for the diagnosis of ALS.1 Nevertheless, several
neurological, clinical neurophysiological and neuropathological
studies have suggested that ALS is a more generalised
neurodegenerative disorder.2–16
The aim of this study was to determine the incidence of
patients with ALS with electrophysiological sensory nerve
abnormalities and to examine the possible differences between
patients with ALS with normal versus abnormal sensory nerve
conduction studies (NCS). The study was carried out on the
basis of electrodiagnostic examinations of 88 patients with ALS
included in the European multicentre project ESTEEM
(European Standardised Telematic tool to Evaluate
Electrodiagnostic Methods).17
METHODS
Patient collection
Seven clinical neurophysiologists from six different European
countries prospectively collected 159 anterior horn cell disorder
examinations from 1995 to 2003. Three doctors submitted 24
consecutive examinations, whereas the rest submitted 23, 22,
21 and 21 each. All doctors were experienced consultants, who
examined the patients following regular electrophysiological
examination routines. Skin temperature was maintained at
between 32 and 35 C˚ for all NCS.
All information from the examinations was transferred to an
electronic data format, including standardised data from
electrophysiological recordings and free text clinical informa-
tion. The examinations were peer reviewed by the regular
ESTEEM procedure, including discussions at workshop meet-
ings, with the primary goal of reaching a consensus on the
diagnosis.17 Firstly, an electrodiagnostic consensus diagnosis
based solely on the electrophysiological data was sought.
Secondly, to reach a final consensus diagnosis, all clinical
neurological, biochemical and radiological data, in addition to
the electrophysiological data, were reviewed. Information on
quantitative sensory testing, as well as the nutritional status of
the patients, was not systematically recorded. However, severe
weight loss, vitamin B12 deficiency or any other medical
condition was noted.
Selection criteria
The group’s consensus diagnosis of ALS was based on the
following criteria1:
N Clinical and electromyographic evidence of progressive LMN
degeneration
N Clinical evidence of UMN degeneration
N LMN and UMN signs in at least two of the four central
nervous system regions: brain stem, cervical, thoracic or
lumbosacral spinal cord
N Clear progression of the disease.
Enrolment in this study further required:
N No evidence of diabetes mellitus, malignancy, paraprotei-
naemia, nutritional deficiency or other known potential
causes of polyneuropathy
N No family history of ALS
N Being an ambulatory patient
N Confirmation of ALS diagnosis by follow-up.
Patients with ALS
In all, 88 patients (48 women and 40 men) were included in the
study (fig 1). The mean age was 63.6 years (range 36–85) and
the mean duration from onset of symptoms to electrophysio-
logical examination was 10.2 months (range 2–48). Limb onset
was reported in 61 patients and bulbar onset in 23, and a
combination of limb and bulbar onset was reported in 4
patients.
Abbreviations: ALS, amyotrophic lateral sclerosis; ESTEEM, European
Standardised Telematic Tool to Evaluate Electrodiagnostic Methods; GSSA,
generalised sensory system abnormalities; LMN, lower motor neurone;
NCS, nerve conduction studies; SNAP, sensory nerve action potential;
SNCV, sensory nerve conduction velocity; UMN, upper motor neurone
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The patients were divided into three subgroups according to
the consensus diagnosis and the sensory NCS findings, with
nerve abnormality defined as a decrease in sensory nerve
conduction velocity (SNCV) or a decrease in amplitude of the
sensory nerve action potential (SNAP) of minimum 2 standard
deviations from the mean of controls according to the locally
used normative values.18 The groups were defined as follows:
N ALS: Patients with normal sensory NCS findings.
N ALS+GSSA: Patients with generalised sensory system
abnormalities (GSSA). In addition to the main diagnosis of
ALS, these patients obtained a peer review diagnosis of
electrophysiological polyneuropathy, including abnormal
NCS findings in at least two sensory nerves. The pathophy-
siological changes in these patients are, however, referred to
as generalised sensory system abnormalities, because per-
ipheral neuropathy and, for example, sensory neuronopathy
cannot be distinguished by electrophysiological data.
N ALS+possible GSSA: Patients with abnormal sensory NCS
findings in at least one nerve.
Control group
A control group comprising 100 consecutive age-matched
patients (mean age 55.8 years; range 36–87) from the
ESTEEM database with a main diagnosis other than poly-
neuropathy or anterior horn cell disorder was used to assess the
frequency of an additional diagnosis of polyneuropathy by this
particular group of doctors.
Statistical analysis
Continuous variables were compared among all three groups
using the Kruskal–Wallis non-parametric analysis of variance,
and between the ALS+GSSA and ALS groups using the Mann–
Whitney U test for independent samples. Proportions were
compared using the x2 statistics. p Values ,0.05 were
considered significant.
RESULTS
Of the 88 patients with ALS, 68 (77.3%) patients were entered
into the ALS group, 11 (12.5%) patients into the ALS+GSSA
group and 9 (10.3%) patients into the ALS+possible GSSA
group. The incidence of patients with additional consensus
diagnosis of polyneuropathy was significantly higher in the ALS
group than in the control group (12.5% v 2.0%; p,0.01).
Comparison of sex, disease duration and region of onset
among the three subgroups of patients with ALS did not show
any differences. The mean age in the three groups was ALS:
62.7 years (range 36–85); ALS GSSA: 69.3 years (range 50–81);
and ALS+possible GSSA: 62.8 years (range 52–77). The mean
duration to examination in the three groups was ALS:
10.4 months (range 2–48); ALS+GSSA: 10 months (range 2–
24); and ALS+possible GSSA: 8.9 months (range 3–30). The
frequency of patients with bulbar onset was ALS: 26%;
ALS+GSSA: 27%; and ALS+possible GSSA: 22%.
When comparing the ALS+GSSA and ALS groups separately,
the average number of sensory nerves examined per patient
was higher in the ALS+GSSA group (3.7 v 2.8; p = 0.04).
Furthermore, there was a tendency (p = 0.09) towards older
age of the patients in the ALS+GSSA group.
No sensory deficits on neurological examination were
reported in any of the patients in the ALS+GSSA or
ALS+possible GSSA groups.
Electrophysiological findings
Of 41 sensory nerves examined in the ALS+GSSA group, 32
(78%) nerves had abnormal SNC parameters: 6 had decreased
SNCV and decreased SNAP amplitude, 10 had decreased SNCV,
14 had decreased SNAP amplitude and 2 nerves did not elicit
any response (table 1). Of the 41 sensory nerves examined in
the ALS+possible GSSA group, 15 (37%) nerves had electro-
physiological deficits: 5 had decreased SNCV and SNAP
amplitude, 7 had decreased SNAP amplitude, 2 had decreased
SNCV and 1 nerve did not yield any sensory response. None of
the abnormalities in any of the patients in the two groups was
due to nerve entrapment.
DISCUSSION
In this study, 20 (22.7%) patients from a series of 88 patients
with ALS sampled by an international group of seven
experienced neurophysiologists showed abnormalities in sen-
sory NCS parameters. The doctors, serving as a peer review
group, furthermore diagnosed 11 (12.5%) patients with
additional electrophysiological polyneuropathy. This proportion
clearly exceeds the reported frequencies of polyneuropathy in
the background population by 0.04–0.1%, and the 1.6%
prevalence of polyneuropathy in patients .55 years with no
recognised exposure to diseases or neurotoxic agents found
in an Italian multicentre study.19–21 These rates may be
Figure 1 Outline of the group of patients with ALS. Of the 159 patients
with anterior horn cell disorder (AHCD) sampled, 61 were excluded: 11 at
the data validation level because of incomplete data submission (n = 3) or
because of a consensus diagnosis other than anterior horn cell disorder
(n = 8); 43 at the peer review level as they did not meet the established
criteria for ALS (23 primarily due to absence of upper motor neurone signs,
17 primarily due to lower motor neurone signs in one central nervous
system region only or due to unconvincing electromyographic findings, 2
with Kennedy’s disease and 1 with spinal muscular atrophy), 6 with
diabetes mellitus and 1 with other systemic disorder. At follow-up, 10
patients with an ALS consensus diagnosis were excluded: 9 patients were
lost to follow-up and 1 patient was excluded as there had been no disease
progression over 5 years.
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underestimated, as they were based on clinical assessment;
higher frequencies are expected when electrodiagnostic tests
are applied.22 However, the frequency of additional polyneuro-
pathy in our age-matched control group comprising patients
with various disorders examined in the involved laboratories
was 2%.
The significantly greater proportion of patients with normal
sensory NCS findings in this study indicates that sensory nerves
are not generally affected in patients with ALS. Rather, patients
with sensory nerve dysfunction may represent a variant of ALS.
The similar disease duration of ,11 months in the three ALS
subgroups indicates that the sensory nerve involvement is part
of the primary disease, which is supported by the non-
progressive subclinical findings of the sensory system in
patients with ALS by Theys et al,7 and the recent quantitative
demonstration of a marked degeneration of sensory axons in
the dorsal roots of the SOD1G93A mouse model of ALS, which
appeared to be non-progressive with advancing disease.23
Although the patients in this study were diagnosed with
electrophysiological peripheral polyneuropathy, the sensory
nerve abnormalities can be generated in the dorsal root
ganglion, as a peripheral sensory axonal neuropathy and a
ganglionopathy cannot be distinguished using electrodiagnostic
methods. Morphological findings of sensory nerve biopsies
from patients with ALS have shown axonal degeneration,
segmental demyelination and a reduced number of large
neurones of the L5 dorsal root ganglion.8–10 12 These findings
and the findings of disparate electrophysiological abnormalities
in this study, not consistently indicative of either axonal loss or
demyelination, are in keeping with the suggestion by Heads et
al10 that the primary pathology in the sensory peripheral nerve
in ALS is dorsal root ganglion neuronopathy, resulting initially
in progressive axonal atrophy followed by secondary de-
remyelination and ultimately by axonal loss.
The revised El Escorial (World Federation of Neurology)
criteria for the diagnosis of ALS allow abnormal sensory NCS
only in the presence of entrapment syndrome or coexisting
peripheral nerve disease.1 Normal sensory NCS have been
shown in a series of patients with ALS.24 25 Other neurophysio-
logical studies have reported frequencies of patients with ALS
with abnormal findings of the peripheral nervous system
ranging between 13% and 22%.3 5–7 In this study, in a few
patients only two sensory nerves were studied or reduced SNCV
was the sole finding. Clearly, caution should be taken in these
Table 1 Electrophysiological findings in the ALS+GSSA and ALS+possible GSSA groups
Group Patient
No of
examined
sensory nerves
Percentage of
abnormal sensory
nerves
Abnormal
nerve(s) SNCV
SNAP
amplitude
ALS+GSSA 1 5 100 Radial Q Q
Median Q Q
Ulnar Q Q
Sural No response
Peroneal No response
2 3 67 Ulnar Q
Sural Q Q
3 2 100 Ulnar Q
Peroneal Q
4 4 50 Median Q
Median Q
5 3 100 Median Q
Ulnar Q
Sural Q
6 4 75 Radial Q
Median Q
Sural Q
7 3 67 Median Q
Ulnar Q
8 4 50 Median Q
Sural Q
9 2 100 Median Q
Ulnar Q
10 8 75 Median Q Q
Median Q Q
Ulnar Q
Sural Q
Peroneal Q
Peroneal Q
11 3 100 Median Q
Sural Q
Sural Q
ALS+possible GSSA 12 4 25 Sural Q
13 5 20 Median Q
14 5 20 Ulnar Q
15 3 67 Ulnar Q
Ulnar Q
16 5 40 Median Q Q
Ulnar No response
17 3 33 Median Q
18 2 50 Median Q Q
19 8 25 Peroneal
Peroneal
Q Q
Q Q
20 6 33 Peroneal
Peroneal
Q
Q
ALS, amyotrophic lateral sclerosis; GSSA, generalised sensory system abnormalities; SNAP, sensory nerve action
potential; SNCV, sensory nerve conduction velocity; Q, decrease.
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cases; however, broad criteria that include the presence of some
electrophysiological sensory abnormality may be appropriate.
Further prospective studies are needed to determine how much
abnormality is allowable in the diagnosis of ALS.
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